BiotechTube
Home/Pipeline/GBR 830

GBR 830

Oncology

Phase 1Active

Key Facts

Indication
Oncology
Phase
Phase 1
Status
Active
Company
Glenmark Pharmaceuticals

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is a research-driven global pharmaceutical company founded in 1977 and headquartered in Mumbai, India. The company operates across the pharmaceutical value chain with significant investments in R&D, particularly in respiratory diseases, dermatology, and oncology. Glenmark has successfully developed and commercialized innovative drugs while building a strong generic pharmaceuticals portfolio across key markets including the US, Europe, and emerging markets.

View full company profile

Therapeutic Areas

RespiratoryDermatologyOncologyCardiovascularCentral Nervous System

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
LockBody Platform AssetsCentessa PharmaceuticalsPre-clinical
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Alymsys (bevacizumab-maly)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved
FocinezAmneal PharmaceuticalsApproved